No Data
CHINARES PHARMA (03320.HK): The total principal amount of the convertible Bonds issued by CHINARES PHARMA Pharmaceutical Commerce in 2024 will not exceed 3 billion yuan.
On December 11, Gelonghui reported that CHINARES PHARMA (03320.HK) announced that, according to the approval issued by the China Securities Regulatory Commission for CHINARES PHARMA Commercial Group Co., Ltd. to publicly issue corporate bonds to qualified investors in China (License No. [2024] 1356), the company's non-wholly-owned subsidiary CHINARES PHARMA Commercial has issued convertible bonds in China. The total issue principal amount of the 2024 convertible bonds will not exceed 3 billion yuan. A total of two varieties of 2024 convertible bonds were issued, with the first variety having a scale of 2.5 billion yuan, an initial term of three years, and a nominal annual interest rate of 2.15.
Express News | China Resources Pharmaceutical Group Ltd - Unit Issued Perpetual Bonds in PRC
Bearish landing? Hong Kong stocks in the pharmaceutical sector collectively strengthen with wuxi apptec rising over 8%.
① How much impact did the biological safety legislation have on domestic pharmaceutical stocks previously? ② How do industry insiders view the subsequent development of the biological legislation?
Hong Kong stock concept tracking | The biocontrol bill was not included in the latest version of NDAA. Institutions are bullish on the bottom opportunities in the CXO sector (with concept stocks attached).
On December 7, 2024, local time in the USA, the US Congressional Armed Services Committees in both the House and the Senate released the final agreement text of the 2025 National Defense Authorization Act (NDAA), which incorporates proposals from both chambers.
Honkong stock market movement | CRO concept stocks collectively opened higher as the bioprotective legislation was not included in the final version of the NDAA by the U.S. Senate and House of Representatives.
CRO concept stocks opened higher collectively. As of the time of writing, wuxi bio (02269) increased by 13.03%, trading at 19.6 Hong Kong dollars; wuxi apptec (02359) rose by 11.72%, trading at 61 Hong Kong dollars; pharmaron (03759) climbed by 9.14%, trading at 16 Hong Kong dollars.
Sinolink Securities: The favorable wind of medical policies arrives first, followed by innovation going abroad and performance reversal.
In 2025, Sinolink believes that the core investment opportunities in the pharmaceutical Sector will revolve around three main logics: 1) innovation going abroad; 2) demand recovery; 3) reversal of policy expectations.
